Replies to post #1864 on Enanta Pharmaceuticals Inc (ENTA)

[DewDiligence]

ENTA's FY2Q20 earnings will likely be soft for two reasons: 1) The Mavyret royalty rate drops to 10% at the beginning of each calendar year and has to work its way back to the higher tiers as the year progresses; and 2) ABBV's Mavyret sales to new patients presumably fell in March, when people started deferring non-essential doctor visits.

I still think ENTA is a strong buyout candidate, FWIW.